Imugene Ltd · ASX:IMU
Imugene — Investor Presentation (May 2021)
18 slides from Imugene's investor presentation, May 18, 2021
Slide 1: Imugene Licenses CD19 Oncolytic Virus to Turn CAR T Therapy Against Solid Tumours
ASX: IMU Imugene Licenses CD19 Oncolytic Virus to Turn CAR T Therapy Against Solid Tumours 18th May 2021
Slide 2: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment 4. Neither the Company nor any of its directors, officers, employees, advisers, advice. The presentation is not intended to be comprehensive or provide all associated persons or subsidiaries are liable for any
Slide 3: Investment Highlights
Investment Highlights Worldwide exclusive license The four FDA approved CD19 Compelling pre-clinical activity OnCARlytics Phase 1 study to CAR T drugs only work in in TNBC, colorectal, pancreatic, commence in 2022 to novel technology which blood cancers- solid tumours prostate, ovarian, head and pro
Slide 4: Introducing onCARlytics
Introducing onCARlytics “OnCARlytics makes the treatment of solid tumours by CAR T drugs viable” Dr Saul Priceman Watch: Combination CAR T Oncolytic Virus Immunotherapy Kills Tumours OnCARlytics is a novel and effective combination immunotherapy utilizing its exclusively licensed CF33 oncolytic viru
Slide 5: The CAR T Solid Tumour Challenge & Imugene's Solution
The CAR T Solid Tumour Challenge & Imugene’s Solution NEW CONCEPT Chimeric Antigen Receptor (CAR) T cell therapy has had limited activity in solid tumours, largely due to a lack of selectively and highly expressed surface antigens, such as the blood B cell antigen Utilise OV’s as a delivery vector t
Slide 6: Mechanism of Action: How does it work?
Mechanism of Action: How does it work? onCARlytics makes solid tumours “seen” by CD19 directed CAR T 1 1. OnCARlytics infects tumour cells 4 2. Virus replication and production of CF33-CD19 on the cell surface 2 enabling CD19 CAR T cell targeting 3. Tumour cell lysis leads to viral particle release
Slide 7: onCARlytics Delivers CAR Targets to "Targetless" Solid Tumours
onCARlytics Delivers CAR Targets to “Targetless” Solid Tumours a A. Immunofluorescence microscopy of MDA- J2R onCARlytics Vaccinia Oncolytic Virus MB-468 cells infected for 24 hours with CF33-CD19 CF33-(SE)hCD19t PSE Vaccinia Virus CF33-CD19 at multiplicity of infection hCD19t CD19 (MOI) of 0.025 or
Slide 8: onCARlytics Drives CD19 CAR T cell Anti-Tumour Responses in Solid Tumours
onCARlytics Drives CD19 CAR T cell Anti-Tumour Responses in Solid Tumours Tumour injection CF33-CD19 CAR T cells Antitumour efficacy of combination therapy of CF33-CD19 and CD19 CAR T cells in human xenograft D0 D36 D46 Monitor tumour growth tumour models. i.t. 10M i.t. 5M Mock or MDA-MB-468 tumour–
Slide 9: onCARlytics promotes endogenous & CAR T cell tumour infiltration
onCARlytics promotes endogenous & CAR T cell tumour infiltration Combination of CF33-CD19 and CD19 CAR T CF33-CD19 + CF33-CD19 + p = 0.0003 cells promotes endogenous cytotoxic T cells, Mock alone CAR alone Mock CAR p = 0.08 CAR T cells & memory T cell responses 1000 Tumor Volume (mm3) CD8+ (cells/fi
Slide 10: CD19 CAR T with onCARlytics Amplifies Intratumoural Virus Spread In Vivo
CD19 CAR T with onCARlytics Amplifies Intratumoural Virus Spread In Vivo p = 0.016 A No treatment CF33-CD19 alone B p = 0.008 60 p = 0.056 Vaccinia (%) 40 20 Combining CD19 CAR T Vaccinia / DAPI 0 with CF33-CD19 CF33-CD19 + Mock CF33-CD19 + CAR p = 0.056 supercharges viral C alo t e e Vm + e t + ck
Slide 11: Published Front Cover of Science Translational Medicine Journal in 2020
Published Front Cover of Science Translational Medicine Journal in 2020 Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumours Park AK, Fong Y, Kim SI, Yang J, Murad JP, Lu J, Jeang B, Chang WC, Chen NG, Thomas SH, Forman SJ, Priceman SJ.Sci Transl Med. 2
Slide 12: Milestones
Milestones Next 12-24 months Ø GMP manufacturing for pre-clinical toxicology & Phase 1 study Ø FDA Pre-IND Meeting Ø GLP Toxicology Study Ø FDA IND Clearance Ø 1st Patient Dosed Monotherapy Ø 1st Patient Dosed Combination Therapy Ø Recommended Phase 2 Dose Established & Expansion Opened 12
Slide 13: Four FDA Approved CD19 CAR T's
Four FDA Approved CD19 CAR T’s Approved and in-development autologous or allogeneic CD19 CAR Ts can be partnered with Imugene’s onCARlylics for treating solid tumours: 13
Slide 14: onCARlytics Management Team
onCARlytics Management Team Leslie Chong MD & CEO Dr Yuman Fong Dr Saul Priceman Dr Anthony Park CAR T Cell Therapy Dr Nick Ede Dr Rita Laeufle Inventor Inventor Inventor Expert Chief Technology Officer Chief Medical Officer Chief Business Officer 14
Slide 15: Intellectual Property
Intellectual Property FOU N DATI ON PATEN T ( 2 0 3 8 ) PCT US2019/033030 Oncolytic virus expressing a CAR T Title cell target and uses thereof Fong, Priceman, Forman, Chen Inventors & Park Assignee City of Hope Primary Date 11 August 2017 International Publication 14 February 2019 Expiration Date 2
Slide 16: Three Novel Technology Platforms
Three Novel Technology Platforms onCARlytics CF33 Oncolytic Virus B Cell Immunotherapy CHECKvacc VAXINIA CF33-CD19 CAR T Combination Therapy HER-Vaxx PD1-Vaxx “Armed” Virus Parental Virus B-Vaxx, PDL1-Vaxx, LAG3-Vaxx, TIM3-Vaxx, VEGF-Vaxx, CTLA4-Vaxx etc 16
Slide 17: Summary and Projections
Summary and Projections OnCARlytics Phase 1 study to commence in 2022 WORLDWIDE THE FOUR FDA OFFERS IMUGENE EXCLUSIVE APPROVED NUMEROUS PARTNERING OR license to novel technology CD19 CAR T drugs only COLLABORATION which provides Imugene’s CF33 oncolytic virus the work in blood cancers… OPPORTUNITIES
Slide 18: Leslie Chong Managing Director & CEO
Leslie Chong Managing Director & CEO leslie.chong@imugene.com +61 458 040 433